Posted on:
Nov 20, 2017 10:31PM
- edited
Nov 20, 2017 10:35PM
by
lumpie
L
Joined:
Nov 2015
Posts:
1,650
Latest activity:
Feb 16, 2023
Posted on:
Nov 20, 2017 10:31PM
- edited
Nov 20, 2017 10:35PM
by
lumpie
lumpie
wrote:
I watch for research news on breast cancer, treatments, etc., and frequently see interesting articles. There is a topic on BCO called "Breaking Research News from Breastcancer.org." One of the moderators suggested that another topic might be appropriate for posting links and synopses of reports on research found elsewhere. So here it is! Please post links to reports on research form reliable sources. Thanks for sharing!
"We must be willing to let go of the life we have planned, so as to have the life that is waiting for us." "If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride."
Dx
2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2-
Chemotherapy
1/13/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel)
Targeted Therapy
1/14/2016 Herceptin (trastuzumab)
Dx
2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2-
Surgery
Lumpectomy; Lumpectomy (Right)
Surgery
Lumpectomy; Lumpectomy (Right)
Radiation Therapy
Whole breast: Breast
Log in to post a reply
T
threetree
Joined:
Nov 2019
Posts:
1,004
Latest activity:
Mar 22, 2023
Log in to post a reply
Feb 8, 2023 03:49PM
threetree
wrote:
SarahMaude - Thanks for sharing such a good post. Their conclusions pretty well fit with my experience, and you are so right about how it will take some real time to get what we had again - even if they do actually fix things.
D
debbew
Joined:
Apr 2019
Posts:
239
Latest activity:
Mar 23, 2023
Log in to post a reply
Mar 10, 2023 08:36AM
debbew
wrote:
[mouse study] Two-pronged immunotherapy eliminates [bone-only] metastatic breast cancer in mice
...The researchers investigated two models of human metastatic breast cancer in mice and found that the metastatic tumors were eliminated in mice that received a p38MAPK inhibitor and an immune therapy called an OX40 agonist, which binds and activates T cells. All these mice were still alive and tumor-free at least 80 days after treatment. Among mice receiving either of the two treatments alone, only about half of them were still alive 60 days after treatment.
Three different OX40 agonists are being investigated in phase 2 clinical trials for cancer, including breast cancer. And p38MAPK inhibitors have been investigated in a number of inflammatory disorders, including rheumatoid arthritis and chronic obstructive pulmonary disease.
"We are hopeful that our study will interest companies that make these drugs, so that we can work toward developing a clinical trial that could investigate this strategy in patients with metastatic breast cancer," Stewart said...
https://www.sciencedaily.com/releases/2023/03/2303...
T
threetree
Joined:
Nov 2019
Posts:
1,004
Latest activity:
Mar 22, 2023
Log in to post a reply
Mar 10, 2023 09:28AM
threetree
wrote:
Debbew - I saw this yesterday myself and almost posted it here. I've got some super bad pulled back muscles though, and am trying to reduce a lot of my activities overall. I'm still posting a bit (can't seem to stay away from this site for too long), but not quite as much as some days.
I was very encouraged when I read this ScienceDirect article, but as always it looks like it's light years away from anything that a lot of us might be able to benefit from. Also, we all know the risks and the side effects that can come with the immune therapy agents, but they never spoke to the possible side effects and risks of these T cell boosters, and the inhibitor.
I'd really like to see this turn into something seriously useful soon, but then I think of how promising ERso looked.
Here's hopin'!